Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics, 16872-16874 [2019-08167]

Download as PDF 16872 Federal Register / Vol. 84, No. 78 / Tuesday, April 23, 2019 / Notices ANNUAL BURDEN ESTIMATES—Continued Total number of respondents Instrument HPOG 2.0 National Evaluation descriptive study second round telephone interview protocol .................................. HPOG 2.0 National Evaluation descriptive study program operator interview guide ................................................... HPOG 2.0 National Evaluation descriptive study partner interview guide ................................................................. HPOG 2.0 National Evaluation descriptive study participant in-depth interview guide ........................................... Intermediate follow-up survey for the HPOG 2.0 National Evaluation impact study ................................................... HPOG 2.0 National Evaluation impact study instrument for a Pilot Study of Phone-Based Skills Assessment ........... HPOG 2.0 National Evaluation program cost survey .......... Number of responses per respondent Authority: Section 2008 of the Social Security Act as enacted by Section 5507 of the Affordable Care Act. Mary B. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2019–08163 Filed 4–22–19; 8:45 am] BILLING CODE 4184–72–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Submission for OMB Review; State Access and Visitation Grant Application (OMB #0970–0482) Office of Child Support Enforcement, Administration for Children and Families, HHS. ACTION: Request for public comment. AGENCY: The Office of Child Support Enforcement is requesting a three-year Annual burden hours 63 1 1.25 79 16 5 1 1.25 6 112 37 1 1 37 140 47 1 1.33 63 4,000 1,333 1 1 1,333 300 38 100 13 1 1 .75 7 75 91 Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: OIRA_ SUBMISSION@OMB.EOP.GOV, Attn: Desk Officer for the Administration for Children and Families. Copies of the proposed collection may be obtained by emailing infocollection@ acf.hhs.gov. Alternatively, copies can also be obtained by writing to the ADDRESSES: Administration for Children and Families Average burden hours per response 190 extension of the application form titled, Child Access and Visitation Grant Application Form, expiration 8/31/ 2019. There are no changes requested to the form. DATES: Comments due within 30 days of publication. OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the Federal Register. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Estimated Total Annual Burden Hours: 1,691. SUMMARY: Annual number of respondents Administration for Children and Families, Office of Planning, Research, and Evaluation, 330 C Street SW, Washington, DC 20201, Attn: OPRE Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection. SUPPLEMENTARY INFORMATION: Description: The application compiles detailed information regarding program administration, services planned, state priorities, and program safeguards for using grant funds to increase noncustodial parent access to and visitation with their children. This information allows OCSE to review states’ Access and Visitation services for the purpose of ensuring compliance with federal regulation and to provide enhanced targeted technical assistance as indicated. The application is submitted one time at the beginning of a three year grant program cycle and only updated during the three years if a grantee proposes substantive programmatic or administrative change. Respondents: State Governments. ANNUAL BURDEN ESTIMATES Instrument Total number of respondents Number of responses per respondent Average burden hours per response Total burden hours Annual burden hours Child Access and Visitation Grant Application Form ........... 54 1 10 540 180 Estimated Total Annual Burden Hours: 180. jbell on DSK3GLQ082PROD with NOTICES Authority: Sec. 469B. [42 U.S.C.669b]. Mary B. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2019–08109 Filed 4–22–19; 8:45 am] BILLING CODE 4184–41–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Best Pharmaceuticals for Children Act (BPCA) Priority List of Needs in Pediatric Therapeutics AGENCY: National Institutes of Health, HHS. VerDate Sep<11>2014 17:49 Apr 22, 2019 Jkt 247001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 ACTION: Notice. The National Institutes of Health (NIH), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) hereby announces the renewal of the Best Pharmaceuticals for Children Act (BPCA) Program. The Best Pharmaceuticals for Children Act (BPCA) seeks to improve the level of SUMMARY: E:\FR\FM\23APN1.SGM 23APN1 jbell on DSK3GLQ082PROD with NOTICES Federal Register / Vol. 84, No. 78 / Tuesday, April 23, 2019 / Notices information on the safe and effective use of pharmaceuticals used to treat children. The BPCA requires that the NIH identify the drugs of highest priority for study in pediatric populations, publish a list of drugs/ needs in pediatric therapeutics, and fund studies in the prioritized areas. This notice will provide a brief summary of recent changes in the legislation, a brief update on the current progress of the BPCA Program and provide the current Priority List of Needs in Pediatric Therapeutics. ADDRESSES: The complete Priority List of Needs in Pediatric Therapeutics 2018–2019 can be found on the BPCA website at the following address: https://www.nichd.nih.gov/research/ supported/bpca/activities. FOR FURTHER INFORMATION CONTACT: Dr. Perdita Taylor-Zapata via email at taylorpe@mail.nih.gov; or by phone at 301–496–9584. SUPPLEMENTARY INFORMATION: The BPCA requires that the NIH, in consultation with the Food and Drug Administration and experts in pediatric research, identify the drugs and therapeutic areas of highest priority for study in pediatric populations. The NIH BPCA Program has been in existence since 2004 and is overseen by the Obstetric and Pediatric Pharmacology and Therapeutics Branch (OPPTB) of the NICHD. To date, the BPCA Program has prioritized over 150 drugs and therapeutic areas, funded more than 25 clinical studies, and improved the labeling to date of eight drugs and one device in the ongoing effort of advancing the knowledge of dosing, safety and effectiveness of medicines used in children. However, despite these and many other efforts, many gaps in our knowledge still remain regarding the use of therapeutics in children including the correct dosage, appropriate indications, side effects, and safety concerns of pharmaceuticals in the short- and long-term. These gaps result in inadequate labeling and/or wide-spread off-label use of prescription drugs in children. Off-label use of a drug substantially limits the ability to obtain important clinical information for more generalized use of a drug product, such as characterizing changes in drug metabolism and response during growth and development, identifying precisionbased responses (i.e., impact of genotype and phenotype of medication responses, the impact of obesity on dosing), and determining short- and long-term effects. The mandate of the NIH BPCA Program is to fill knowledge gaps that exist in pediatric therapeutics and to promote an increase in evidencebased data about medications used in VerDate Sep<11>2014 17:49 Apr 22, 2019 Jkt 247001 children. Please see the BPCA website for more information: https:// www.nichd.nih.gov/research/supported/ bpca/about. Update on the BPCA Legislation First authorized in 2002, the Best Pharmaceuticals for Children Act (BPCA) has been reauthorized as part of larger Food and Drug Administration (FDA) user fee legislation three additional times: 2007, 2012, and now 2017. The overall mandate for the implementation of the research program at NIH has remained the same throughout, but with clarifications each time: To prioritize testing of pediatric therapeutics that do not have labeling for pediatric use, to sponsor clinical trials and other research to provide the necessary data, and to submit those data to the FDA to begin the process of obtaining label changes and provide clinicians with the appropriate information on appropriate pediatric use and dosing. In August of 2017, the BPCA legislation was reauthorized by Congress, which renewed the NIH BPCA Program for five years (the FDA portion of the program is permanently authorized). The new legislation also permits the NIH to prioritize research on the identification of biomarkers for pediatric diseases and conditions. In addition, a new provision specifically allows the NIH to post the data from the pediatric studies it funded on its public website when it submits the report to the FDA, as required for potential label changes. Update on BPCA Prioritization The BPCA Priority List consists of key therapeutic needs in the medical treatment of children and adolescents identified for further study; it is organized by therapeutic area, which can be a group of conditions, a subgroup of the population, or a setting of care. The first priority list of off-patent drugs needing further study under the 2002 BPCA legislation was published in January 2003 in the Federal Register (FR Vol. 68, No. 13; Tuesday, January 21, 2003: 2789–2790). The most recent priority list has been published to the BPCA website; more information on the prioritization process, all BPCA priority lists, and all Federal Register Notices can be found on the BPCA website: https://www.nichd.nih.gov/research/ supported/bpca/prioritizing-pediatrictherapies. The BPCA authorizing legislation requires the NIH to update the priority list every three years. This Notice serves as an update to the BPCA priority list of needs in pediatric therapeutics. PO 00000 Frm 00038 Fmt 4703 Sfmt 4703 16873 Each year, the NICHD revisits the current list of needs in pediatric therapeutics and seeks input from experts in pediatric research and medicine to determine if previous needs still exist and if new areas of needs have developed. Below is an updated list of therapeutic areas and drugs that have been prioritized for study since the inception of the BPCA and a summary of the NICHD’s plans and progress in all of these areas to date. In 2017, the NIH BPCA Program focused on the following areas: Treatment options in Pediatric Hypertension, Biomarkers in Pediatric Research (various subspecialties), and Treatment strategies in several neonatal conditions (including Neonatal Opioid Withdrawal Syndrome, also known as Neonatal Abstinence Syndrome). Meeting minutes for workshops and lectures on the above topics can be found on the BPCA website https:// www.nichd.nih.gov/research/supported/ bpca/research-initiatives-collaborations. For 2018, the NIH BPCA Program’s priorities have included: Heart failure in children, Kidney diseases, and Lactation (in particular, neonatal and infant medication exposure). The NICHD welcomes input from the pediatric medical community on additional gaps in pediatric therapeutics for future consideration. The most recent BPCA stakeholders meeting was held in Bethesda, Maryland on March 22, 2019. More information will be provided on the BPCA website as it becomes available. All inquiries should be submitted to Dr. Perdita Taylor-Zapata at the contact information above. Priority List of Needs in Pediatric Therapeutics 2018–2019 In accordance with the BPCA legislation, the list outlines priority needs in pediatric therapeutics for multiple therapeutic areas listed below. The complete list can be found on the BPCA website at the following address: https://www.nichd.nih.gov/research/ supported/bpca/activities. D Table 1: Infectious Disease Priorities D Table 2: Cardiovascular Disease Priorities D Table 3: Respiratory Disease Priorities D Table 4: Intensive Care Priorities D Table 5: Bio-defense Research Priorities D Table 6: Pediatric Cancer Priorities D Table 7: Psychiatric Disorder Priorities D Table 8: Neurological Disease Priorities D Table 9: Neonatal Research Priorities D Table 10: Adolescent Research Priorities E:\FR\FM\23APN1.SGM 23APN1 16874 Federal Register / Vol. 84, No. 78 / Tuesday, April 23, 2019 / Notices jbell on DSK3GLQ082PROD with NOTICES D Table 11: Hematologic Disease Priorities D Table 12: Endocrine Disease Priorities and Diseases with Limited Alternative Therapies D Table 13: Dermatologic Disease Priorities D Table 14: Gastrointestinal Disease Priorities D Table 15: Renal Disease Priorities D Table 16: Rheumatologic Disease Priorities D Table 17: Special Considerations. accompanying list of waivers that have been granted in the fourth quarter of calendar year 2018. SUPPLEMENTARY INFORMATION: Section 106 of the HUD Reform Act added a new section 7(q) to the Department of Housing and Urban Development Act (42 U.S.C. 3535(q)), which provides that: 1. Any waiver of a regulation must be in writing and must specify the grounds for approving the waiver; 2. Authority to approve a waiver of a regulation may be delegated by the Dated: April 17, 2019. Secretary only to an individual of Francis S. Collins, Assistant Secretary or equivalent rank, Director, National Institutes of Health. and the person to whom authority to [FR Doc. 2019–08167 Filed 4–22–19; 8:45 am] waive is delegated must also have BILLING CODE 4140–01–P authority to issue the particular regulation to be waived; 3. Not less than quarterly, the DEPARTMENT OF HOUSING AND Secretary must notify the public of all URBAN DEVELOPMENT waivers of regulations that HUD has approved, by publishing a notice in the [Docket No. FR–6101–N–04] Federal Register. These notices (each covering the period since the most Notice of Regulatory Waiver Requests recent previous notification) shall: Granted for the Fourth Quarter of a. Identify the project, activity, or Calendar Year 2018 undertaking involved; AGENCY: Office of the General Counsel, b. Describe the nature of the provision HUD. waived and the designation of the ACTION: Notice. provision; c. Indicate the name and title of the SUMMARY: Section 106 of the Department person who granted the waiver request; of Housing and Urban Development d. Describe briefly the grounds for Reform Act of 1989 (the HUD Reform approval of the request; and Act) requires HUD to publish quarterly e. State how additional information Federal Register notices of all about a particular waiver may be regulatory waivers that HUD has obtained. approved. Each notice covers the Section 106 of the HUD Reform Act quarterly period since the previous also contains requirements applicable to Federal Register notice. The purpose of waivers of HUD handbook provisions this notice is to comply with the that are not relevant to the purpose of requirements of section 106 of the HUD this notice. Reform Act. This notice contains a list This notice follows procedures of regulatory waivers granted by HUD provided in HUD’s Statement of Policy during the period beginning on October on Waiver of Regulations and Directives 1, 2018 and ending on December 31, issued on April 22, 1991 (56 FR 16337). 2018. In accordance with those procedures and with the requirements of section FOR FURTHER INFORMATION CONTACT: For 106 of the HUD Reform Act, waivers of general information about this notice, contact Ariel Pereira, Associate General regulations are granted by the Assistant Counsel for Legislation and Regulations, Secretary with jurisdiction over the regulations for which a waiver was Department of Housing and Urban requested. In those cases in which a Development, 451 Seventh Street SW, General Deputy Assistant Secretary Room 10282, Washington, DC 20410– granted the waiver, the General Deputy 0500, telephone 202–708–3055 (this is Assistant Secretary was serving in the not a toll-free number). Persons with absence of the Assistant Secretary in hearing- or speech-impairments may accordance with the office’s Order of access this number through TTY by Succession. calling the toll-free Federal Relay This notice covers waivers of Service at 800–877–8339. regulations granted by HUD from For information concerning a October 1, 2018 through December 31, particular waiver that was granted and 2018. For ease of reference, the waivers for which public notice is provided in granted by HUD are listed by HUD this document, contact the person program office (for example, the Office whose name and address follow the of Community Planning and description of the waiver granted in the VerDate Sep<11>2014 17:49 Apr 22, 2019 Jkt 247001 PO 00000 Frm 00039 Fmt 4703 Sfmt 4703 Development, the Office of Fair Housing and Equal Opportunity, the Office of Housing, and the Office of Public and Indian Housing, etc.). Within each program office grouping, the waivers are listed sequentially by the regulatory section of title 24 of the Code of Federal Regulations (CFR) that is being waived. For example, a waiver of a provision in 24 CFR part 58 would be listed before a waiver of a provision in 24 CFR part 570. Where more than one regulatory provision is involved in the grant of a particular waiver request, the action is listed under the section number of the first regulatory requirement that appears in 24 CFR and that is being waived. For example, a waiver of both § 58.73 and § 58.74 would appear sequentially in the listing under § 58.73. Waiver of regulations that involve the same initial regulatory citation are in time sequence beginning with the earliest-dated regulatory waiver. Should HUD receive additional information about waivers granted during the period covered by this report (the fourth quarter of calendar year 2018) before the next report is published (the first quarter of calendar year 2019), HUD will include any additional waivers granted for the fourth quarter in the next report. Accordingly, information about approved waiver requests pertaining to HUD regulations is provided in the Appendix that follows this notice. Dated: April 16, 2019. J. Paul Compton, Jr., General Counsel. Appendix—Listing of Waivers of Regulatory Requirements Granted by Offices of the Department of Housing and Urban Development October 1, 2018 Through December 31, 2018 Note to Reader: More information about the granting of these waivers, including a copy of the waiver request and approval, may be obtained by contacting the person whose name is listed as the contact person directly after each set of regulatory waivers granted. The regulatory waivers granted appear in the following order: I. Regulatory waivers granted by the Office of Community Planning and Development. II. Regulatory waivers granted by the Office of Housing. III. Regulatory waivers granted by the Office of Public and Indian Housing. I. Regulatory Waivers Granted by the Office of Community Planning and Development For further information about the following regulatory waivers, please see the name of the contact person that immediately follows the description of the waiver granted. • Regulation: 24 CFR 92.252(d)(1) Utility Allowance Requirements. E:\FR\FM\23APN1.SGM 23APN1

Agencies

[Federal Register Volume 84, Number 78 (Tuesday, April 23, 2019)]
[Notices]
[Pages 16872-16874]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-08167]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Best Pharmaceuticals for Children Act (BPCA) Priority List of 
Needs in Pediatric Therapeutics

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The National Institutes of Health (NIH), Eunice Kennedy 
Shriver National Institute of Child Health and Human Development 
(NICHD) hereby announces the renewal of the Best Pharmaceuticals for 
Children Act (BPCA) Program. The Best Pharmaceuticals for Children Act 
(BPCA) seeks to improve the level of

[[Page 16873]]

information on the safe and effective use of pharmaceuticals used to 
treat children. The BPCA requires that the NIH identify the drugs of 
highest priority for study in pediatric populations, publish a list of 
drugs/needs in pediatric therapeutics, and fund studies in the 
prioritized areas. This notice will provide a brief summary of recent 
changes in the legislation, a brief update on the current progress of 
the BPCA Program and provide the current Priority List of Needs in 
Pediatric Therapeutics.

ADDRESSES: The complete Priority List of Needs in Pediatric 
Therapeutics 2018-2019 can be found on the BPCA website at the 
following address: https://www.nichd.nih.gov/research/supported/bpca/activities.

FOR FURTHER INFORMATION CONTACT: Dr. Perdita Taylor-Zapata via email at 
[email protected]; or by phone at 301-496-9584.

SUPPLEMENTARY INFORMATION: The BPCA requires that the NIH, in 
consultation with the Food and Drug Administration and experts in 
pediatric research, identify the drugs and therapeutic areas of highest 
priority for study in pediatric populations. The NIH BPCA Program has 
been in existence since 2004 and is overseen by the Obstetric and 
Pediatric Pharmacology and Therapeutics Branch (OPPTB) of the NICHD. To 
date, the BPCA Program has prioritized over 150 drugs and therapeutic 
areas, funded more than 25 clinical studies, and improved the labeling 
to date of eight drugs and one device in the ongoing effort of 
advancing the knowledge of dosing, safety and effectiveness of 
medicines used in children. However, despite these and many other 
efforts, many gaps in our knowledge still remain regarding the use of 
therapeutics in children including the correct dosage, appropriate 
indications, side effects, and safety concerns of pharmaceuticals in 
the short- and long-term. These gaps result in inadequate labeling and/
or wide-spread off-label use of prescription drugs in children. Off-
label use of a drug substantially limits the ability to obtain 
important clinical information for more generalized use of a drug 
product, such as characterizing changes in drug metabolism and response 
during growth and development, identifying precision-based responses 
(i.e., impact of genotype and phenotype of medication responses, the 
impact of obesity on dosing), and determining short- and long-term 
effects. The mandate of the NIH BPCA Program is to fill knowledge gaps 
that exist in pediatric therapeutics and to promote an increase in 
evidence-based data about medications used in children. Please see the 
BPCA website for more information: https://www.nichd.nih.gov/research/supported/bpca/about.

Update on the BPCA Legislation

    First authorized in 2002, the Best Pharmaceuticals for Children Act 
(BPCA) has been reauthorized as part of larger Food and Drug 
Administration (FDA) user fee legislation three additional times: 2007, 
2012, and now 2017. The overall mandate for the implementation of the 
research program at NIH has remained the same throughout, but with 
clarifications each time: To prioritize testing of pediatric 
therapeutics that do not have labeling for pediatric use, to sponsor 
clinical trials and other research to provide the necessary data, and 
to submit those data to the FDA to begin the process of obtaining label 
changes and provide clinicians with the appropriate information on 
appropriate pediatric use and dosing. In August of 2017, the BPCA 
legislation was reauthorized by Congress, which renewed the NIH BPCA 
Program for five years (the FDA portion of the program is permanently 
authorized). The new legislation also permits the NIH to prioritize 
research on the identification of biomarkers for pediatric diseases and 
conditions. In addition, a new provision specifically allows the NIH to 
post the data from the pediatric studies it funded on its public 
website when it submits the report to the FDA, as required for 
potential label changes.

Update on BPCA Prioritization

    The BPCA Priority List consists of key therapeutic needs in the 
medical treatment of children and adolescents identified for further 
study; it is organized by therapeutic area, which can be a group of 
conditions, a subgroup of the population, or a setting of care. The 
first priority list of off-patent drugs needing further study under the 
2002 BPCA legislation was published in January 2003 in the Federal 
Register (FR Vol. 68, No. 13; Tuesday, January 21, 2003: 2789-2790). 
The most recent priority list has been published to the BPCA website; 
more information on the prioritization process, all BPCA priority 
lists, and all Federal Register Notices can be found on the BPCA 
website: https://www.nichd.nih.gov/research/supported/bpca/prioritizing-pediatric-therapies. The BPCA authorizing legislation 
requires the NIH to update the priority list every three years. This 
Notice serves as an update to the BPCA priority list of needs in 
pediatric therapeutics.
    Each year, the NICHD revisits the current list of needs in 
pediatric therapeutics and seeks input from experts in pediatric 
research and medicine to determine if previous needs still exist and if 
new areas of needs have developed.
    Below is an updated list of therapeutic areas and drugs that have 
been prioritized for study since the inception of the BPCA and a 
summary of the NICHD's plans and progress in all of these areas to 
date. In 2017, the NIH BPCA Program focused on the following areas: 
Treatment options in Pediatric Hypertension, Biomarkers in Pediatric 
Research (various subspecialties), and Treatment strategies in several 
neonatal conditions (including Neonatal Opioid Withdrawal Syndrome, 
also known as Neonatal Abstinence Syndrome). Meeting minutes for 
workshops and lectures on the above topics can be found on the BPCA 
website https://www.nichd.nih.gov/research/supported/bpca/research-initiatives-collaborations.
    For 2018, the NIH BPCA Program's priorities have included: Heart 
failure in children, Kidney diseases, and Lactation (in particular, 
neonatal and infant medication exposure). The NICHD welcomes input from 
the pediatric medical community on additional gaps in pediatric 
therapeutics for future consideration. The most recent BPCA 
stakeholders meeting was held in Bethesda, Maryland on March 22, 2019. 
More information will be provided on the BPCA website as it becomes 
available. All inquiries should be submitted to Dr. Perdita Taylor-
Zapata at the contact information above.

Priority List of Needs in Pediatric Therapeutics 2018-2019

    In accordance with the BPCA legislation, the list outlines priority 
needs in pediatric therapeutics for multiple therapeutic areas listed 
below. The complete list can be found on the BPCA website at the 
following address: https://www.nichd.nih.gov/research/supported/bpca/activities.

[ssquf] Table 1: Infectious Disease Priorities
[ssquf] Table 2: Cardiovascular Disease Priorities
[ssquf] Table 3: Respiratory Disease Priorities
[ssquf] Table 4: Intensive Care Priorities
[ssquf] Table 5: Bio-defense Research Priorities
[ssquf] Table 6: Pediatric Cancer Priorities
[ssquf] Table 7: Psychiatric Disorder Priorities
[ssquf] Table 8: Neurological Disease Priorities
[ssquf] Table 9: Neonatal Research Priorities
[ssquf] Table 10: Adolescent Research Priorities

[[Page 16874]]

[ssquf] Table 11: Hematologic Disease Priorities
[ssquf] Table 12: Endocrine Disease Priorities and Diseases with 
Limited Alternative Therapies
[ssquf] Table 13: Dermatologic Disease Priorities
[ssquf] Table 14: Gastrointestinal Disease Priorities
[ssquf] Table 15: Renal Disease Priorities
[ssquf] Table 16: Rheumatologic Disease Priorities
[ssquf] Table 17: Special Considerations.

    Dated: April 17, 2019.
Francis S. Collins,
Director, National Institutes of Health.
[FR Doc. 2019-08167 Filed 4-22-19; 8:45 am]
BILLING CODE 4140-01-P


This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.